Insulin glargine biosimilar - Biocon/Mylan

Drug Profile

Insulin glargine biosimilar - Biocon/Mylan

Alternative Names: Basalog; GALACTUS

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Biocon
  • Developer Biocon; Mylan; PiSA Farmaceutica
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 03 Nov 2016 Preregistration for Type-1 diabetes mellitus (In adults, In adolescents, In children) in European Union (SC)
  • 03 Nov 2016 Preregistration for Type-2 diabetes mellitus (In adults) in European Union (SC)
  • 15 Jul 2016 Launched for Type-1 diabetes mellitus in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top